Gilead posts early Phase 1 data for once-yearly HIV PrEP therapy
Gilead (NASDAQ:GILD) on Tuesday announced encouraging initial data from an ongoing Phase 1 trial for lenacapavir, an ...
Fierce Biotech4d
GSK posts data on HIV assets vying for roles in 6-month combo
GSK’s ViiV Healthcare has shared clinical data on three potential long-acting HIV treatments, providing a look at how its ...
Study examines a novel way to bring addiction care and HIV prevention to people who inject drugs
Researchers from the HIV Prevention Trials Network (HPTN) have presented results from the HPTN 094 ("INTEGRA") study at the ...
My Boyfriend Tested Positive for HIV. I’m Afraid I’m Staying Out of Pure Obligation.
Let’s take your partner’s HIV status out of the equation for a moment. You’re looking at a person who has a concerning temper, refuses to admit faults (and, therefore, probably refuses to work on them ...
US biochemist researching treatment of HIV and coronaviruses wins Israel's Wolf Prize
An American biochemist whose research has helped scientists make inroads on treating coronavirus and HIV has won this year’s Wolf Prize, a major Israeli award in the arts and sciences ...
Amsterdam News6dOpinion
OP-ED: Prioritizing Women for HIV Prevention and Treatment
The U.S. faces an ongoing HIV epidemic, with women, particularly women of color, bearing a heavy burden. While there have ...
Seeking Alpha5d
Gilead posts early Phase 1 data for once-yearly HIV PrEP therapy
The trial enrolled 40 healthy adults aged 18-55 who had a low risk for HIV infection. “Once-yearly lenacapavir, if approved, could become an important new HIV prevention option that could help ...